389 related articles for article (PubMed ID: 24052624)
1. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.
Wang Q; Bailey CG; Ng C; Tiffen J; Thoeng A; Minhas V; Lehman ML; Hendy SC; Buchanan G; Nelson CC; Rasko JE; Holst J
Cancer Res; 2011 Dec; 71(24):7525-36. PubMed ID: 22007000
[TBL] [Abstract][Full Text] [Related]
3. Metastatic castration-resistant prostate cancer hungers for leucine.
Tee AR
J Natl Cancer Inst; 2013 Oct; 105(19):1427-8. PubMed ID: 24052625
[No Abstract] [Full Text] [Related]
4. Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth.
Wang Q; Grkovic T; Font J; Bonham S; Pouwer RH; Bailey CG; Moran AM; Ryan RM; Rasko JE; Jormakka M; Quinn RJ; Holst J
ACS Chem Biol; 2014 Jun; 9(6):1369-76. PubMed ID: 24762008
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
Otsuki H; Kimura T; Yamaga T; Kosaka T; Suehiro JI; Sakurai H
Prostate; 2017 Feb; 77(2):222-233. PubMed ID: 27696482
[TBL] [Abstract][Full Text] [Related]
6. EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer.
Zhang BK; Moran AM; Bailey CG; Rasko JEJ; Holst J; Wang Q
Cell Commun Signal; 2019 Jul; 17(1):83. PubMed ID: 31345230
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
Rii J; Sakamoto S; Sugiura M; Kanesaka M; Fujimoto A; Yamada Y; Maimaiti M; Ando K; Wakai K; Xu M; Imamura Y; Shindo N; Hirota T; Kaneda A; Kanai Y; Ikehara Y; Anzai N; Ichikawa T
Cancer Sci; 2021 Sep; 112(9):3871-3883. PubMed ID: 34050700
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
9. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
13. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
14. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Gregory CW; Johnson RT; Presnell SC; Mohler JL; French FS
J Androl; 2001; 22(4):537-48. PubMed ID: 11451350
[TBL] [Abstract][Full Text] [Related]
16. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
17. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
18. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
20. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.
Shiota M; Yokomizo A; Kashiwagi E; Takeuchi A; Fujimoto N; Uchiumi T; Naito S
Free Radic Biol Med; 2011 Jul; 51(1):78-87. PubMed ID: 21539911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
